Hematologic Malignancies

HIV Drug Shows Promise in Refractory Multiple Myeloma

Charles Bankhead

February 2017, Vol 8, No 1 - Multiple Myeloma

San Diego, CA—Nelfinavir (Viracept), a drug used for HIV, led to a surprisingly high response rate when added to bor­tezomib (Velcade) in patients with proteasome inhibitor–refractory multiple myeloma, according to a phase 2 study reported by Christoph Driessen, MD, myeloma specialist, Kantonsspital St. Gallen, Switzerland, at the 2016 American Society of Hematology meeting. [ Read More ]

American Society of Hematology 2016: Leukemia Highlights

February 2017, Vol 8, No 1 - Leukemia

  • 5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL
  • Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
  • Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
  • Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL
  • Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL
[ Read More ]

American Society of Hematology 2016: Multiple Myeloma Highlights

February 2017, Vol 8, No 1 - Multiple Myeloma

  • Adding Daratumumab to Lenalidomide and Dexamethasone in Previously Treated Patients with Relapsed or Refractory Multiple Myeloma Improves Outcomes
  • Real-World Evidence Regarding Newer Treatment Options, Overall Survival, and Healthcare Costs in Patients with Multiple Myeloma
  • Long-Term Analysis of the CASTOR Trial: Adding Daratumumab to Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
  • The Use of Early Response Can Guide Treatment Selection in Patients with Newly Diagnosed Multiple Myeloma
  • Using Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma
[ Read More ]

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

February 2017, Vol 8, No 1 - Multiple Myeloma

San Diego, CA—The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting. [ Read More ]

Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Multiple Myeloma

Interim results from a phase 1b study indicate that the investigational monoclonal antibody isatuximab, in combination with lenalidomide and dexamethasone, achieves responses in >50% of patients with relapsed or refractory multiple myeloma, including those with disease refractory to immunomodulatory drugs (IMiDs).

[ Read More ]

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Multiple Myeloma

Adding the recently approved daratumumab (Darzalex), a human, CD38-directed monoclonal antibody, to a standard regimen of bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by >60% compared with the standard regimen in patients with relapsed or refractory multiple myeloma, according to Antonio Palumbo, MD, Chief of the Multiple Myeloma Unit, University of Torino, Italy.

[ Read More ]